News >

SOLO-1 Paves Path for Frontline Maintenance in Ovarian Cancer

Ellie Leick
Published: Thursday, Aug 01, 2019

Hye Sook Chon, MD

Hye Sook Chon, MD

The phase III SOLO-1 trial led to olaparib (Lynparza) becoming the first PARP inhibitor to receive regulatory approval as frontline maintenance treatment in ovarian cancer, marking one of the key advances within this paradigm over the last decade, explained Hye Sook Chon, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Publication Bottom Border
Border Publication
x